ArticleThe oncologist2026
First report of dual KRAS Y96C/Y96S resistance mutations detected by liquid biopsy in KRAS G12C-mutant metastatic colorectal cancer.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAcquired resistance limits the long-term efficacy of KRAS G12C inhibitors in metastatic colorectal cancer (mCRC). While feedback signaling is a known resistance driver, the clinical evolution of structural alterations within the drug-binding pocket remains poorly characterized. CASE PRESENTATION: We present a patient with microsatellite-stable (MSS) KRAS G12C-mutated mCRC who progressed after 9.3 months of sequential KRAS G12C inhibitor monotherapy. Comparative molecular profiling of baseline tissue and post-progression plasma ctDNA identified the de novo emergence of concurrent KRAS Y96S and Y96C mutations. These polyclonal Switch II pocket alterations, absent in pretreatment specimens, indicated convergent evolution under therapeutic selective pressure. A rationale-based salvage therapy utilizing vertical MAPK pathway blockade (sotorasib, cetuximab, and trametinib) failed to achieve durable control (PFS: 1.9 months), confirming biological refractoriness.
conclusionThe acquisition of polyclonal KRAS Y96S/C mutations represents a definitive structural resistance mechanism that compromises the efficacy of intensified vertical pathway blockade. The discordance between tissue and liquid biopsy findings underscores the necessity of plasma-based monitoring to capture spatial heterogeneity. These findings suggest that overcoming convergent Switch II pocket remodeling requires next-generation inhibitors with distinct binding modes rather than further pathway intensification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.